Breakthrough device planned to be inproduction by mid 2019, offering frontier solution for the medical market
MIGDAL HAEMEK, Israel, March 5, 2019 – Axbio Inc., a silicon valley basedhigh-end development company providing leading edge solutions for the medicalmarket and TowerJazz,the global specialty foundry leader,, today announced the release of amicrofluidics Bio-CMOS device for molecular in vitro diagnostic (IVD), based onTowerJazz’s 65nm RFCMOS platform, following a successfuldevelopment in its 300mm manufacturing facility in Uozu, Japan. This uniquedevice, planned to be in production by mid-2019, combined with highlyinnovative automation features and disposable cartridge, offers a frontiersolution for the medical market.
This technological breakthrough device enables tests tobe handled on premises, in the clinical lab itself, with no need to send bloodsamples out for results. In addition, minimal blood draw is required forcomplete diagnostics making it highly efficient, facilitating time and costsavings, while enabling extremely accurate and thorough results in a very shortperiod of time with minimal effort.
Axbio’s microfluidic-CMOS platform device and systems areexpected to provide leading-edge technologies in many health-relatedapplications, such as molecular diagnostics, drug discovery, liquid biopsy,microbiology, agriculture, and environmental science.
TowerJazz’s 65nm RFCMOS platform supports a wide range ofCMOS and RF applications with state-of-the-art RF modeling for MOSFETs,inductors and transmission lines, a very large set of metal combination and afull set of RFCMOS elements. RF applications such as WiFi 802.11, WirelessHDMI, and WiGi, that require 65nm mmWave technology, can now utilize modelingcapabilities up to 110GHz. The Company’s customized process solutions, togetherwith its optimized layout, is answering the extremely unique technologicaldemands of the IVD market by allowing ultra-high density (UHD) of sensing arrayalong with extremely high-resolution capabilities. In addition, this platformis automotive qualified.
“We selected TowerJazz because of their high flexibilityand capabilities to adapt their advanced 65nm RFCMOS platform to integrate withour microfluidic technology. TowerJazz’s vast manufacturing expertise isenabling us to successfully fulfill the needs of several market sectorscombined with increased performance required in next-generation IVD systems.TowerJazz has been our development partner for several years and together wehave achieved technology maturity leading to expanded business opportunities,”said Dr. Hui Tian, CEO of Axbio Inc.
“Axbio’s IP, along with TowerJazz’s advanced process,manufacturing capabilities and know-how, enable us to deliver high-end,competitive embedded solutions in multiple markets. Through our partnershipwith Axbio, we are expanding our RFCMOS presence into the growing IVD systemsand medical markets”, said Shimon Greenberg, Vice President and General Managerof Mixed-Signal & Power Management Business Unit, TowerJazz.
About Axbio Inc.
Axbio is a Silicon Valley startup company withdevelopment groups in the US, China and Europe. The company was founded byexperts in semiconductor, chip development, nanotechnology, microfluidics,biotechnologies, and bioinformatics with proven record of successfullylaunching many high volume products. The team develops microfluidics Bio-CMOSplatform capable of high-throughput sequencing and molecular diagnostics.Versatility of the platform enables manufacturing a broad range of systems;from low cost handheld devices for point-of-care offices and consumers to fullyautomated instruments for independent laboratories and hospitals. Axbioprovides sequencing and diagnostic systems, as well as disposable biochips andreagents. Typical applications include fast cancer diagnostics, rapid pathogendetection, and drug development where accuracy, speed, and cost ofcomprehensive tests are of utmost importance. For more information, pleasevisit: www.axbio.cn.
About TowerJazz
Tower Semiconductor Ltd. (NASDAQ: TSEM, TASE: TSEM) andits subsidiaries operate collectively under the brand name TowerJazz, theglobal specialty foundry leader. TowerJazz manufactures next-generationintegrated circuits (ICs) in growing markets such as consumer, industrial,automotive, medical and aerospace and defense. TowerJazz’s advanced technologyis comprised of a broad range of customizable process platforms such as: SiGe,BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, integrated power management(BCD and 700V), and MEMS. TowerJazz also provides world-class design enablementfor a quick and accurate design cycle as well as Transfer Optimization anddevelopment Process Services (TOPS) to IDMs and fabless companies that need toexpand capacity. To provide multi-fab sourcing and extended capacity for itscustomers, TowerJazz operates two manufacturing facilities in Israel (150mm and200mm), two in the U.S. (200mm) and three facilities in Japan (two 200mm andone 300mm). For more information, please visit www.towerjazz.com.
Contacts:
AXBIO INC. Contact:
Angela Zheng| +86 15813845790 | zhengs@axbio.cn
TowerJazz Company Contact:
Orit Shahar | +972-74-7377440 | oritsha@towersemi.com
The original link：http://go.towerjazz.com/e/66962/2019-03-05-03052019-/bpsxn7/384284332?h=0o-5y2NODAby_kDut9ozWKpOI0qjosX0X9IvrKmy1gk
Axbio and TowerJazz Announces Successful Development of In-Vitro Diagnostic Bio-CMOS IC using its Advanced 300mm 65nm RFCMOS Platformd!
- December 11, 2019
- 6:29 am
